Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
1 
  
Abbreviated Title:    Image Guided Focal Prostate  
CC Protocol #: 11 -C-0158  
NCT #:  [STUDY_ID_REMOVED]  
Version Date: 07/13/2017  
Amendment: G 
 
Title:  MR Image Guided Focal Therapy in Prostate Cancer  
 
NCI Principal Investigator:   Peter Pinto, M.D. , UOB , CCR, NCI A, B, C, D, E, F 
 10 Center Drive, 10 -CRC/2 -5952  
Bethesda, MD  20892 -1107  
Telephone:  240-760-6249   
                                                  E-mail: pintop@mail.nih.gov  
 
NIH Associate Investigators:   Bradford J Wood, M.D. , CC, NIH A, B 
      Peter Choyke, M.D. , MIP, CCR, NCI  A, B 
     Baris Turkbey, M.D. , MIP, CCR, NCI  A, B 
     Michele Diffenderfer, R.N., OCD, CCR, NCI A, B, C, E, F 
Joanna Shih, Ph.D., DCTD, NCI E, F  
 
Referral Contact /   Michele Diffenderfer, R.N., OCD, CCR, NCI  
Study Coordinator:    Building 10 CRC, Room B2L324A  
      10 Center Drive  
     Bethesda, MD  20892  
     Phone: 240-760-6121  
     Email: michele.diffenderfer@nih.gov  
 
Investigator Roles:  
 
A. Obtain information by intervening or interacting with living individuals for research purposes  
B. Obtaining identifiable private information about living individuals  
C. Obtaining the voluntary informed consent of individuals to be subjects  
D. Makes decisions about subject eligibility  
E. Studying, interpreting, or analyzing identifiable private information or data/specimens for research 
purposes  
F. Studying, inte rpreting, or analyzing de -identified data or specimens for research purposes  
G. Some/all research activities performed outside NIH  
 
Commercial Device: Visualase Thermal Therapy System (Medtronic)  
Identifying words : toxicity, thermal ablation, localized prosta te cancer, thermal damage, 
Visualase, PSA levels  
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
2 
 PRÉCIS  
Background:  
• Pilot study is designed to evaluate the safety and feasibility of thermal laser ablation of 
focal prostate tumors.   
• Prostate cancer is relatively slow growing, with doubling times for local tumors estimated 
at 2 to 4 years.  
• Some prostate cancers prove to be small, low grade, and noninvasive and they appear to 
pose little risk to the life or health of the host. Recent p atient series suggest that 20% to 
30% of men undergoing radical prostatectomy have pathologic features in the radical 
prostatectomy specimen consistent with an insignificant or "indolent" cancer which poses 
little threat to life or health.  
• We propose that patients with low volume and low grade disease can be best served with 
focal ablation of the visible prostate cancer without the side effects of urinary 
incontinence and erectile dysfunction associated with radiation therapy or radical surg ery.   
 
Primary Objective:  
• To determine feasibility and safety of magnetic resonance image -guided focal laser 
ablation of biopsy confirmed and MR visible prostate cancer.  
 
Eligibility:  
• Greater than 18 years of age  
• Organ confined prostate cancer, observed o n MR, and confirmed by Transrectal biopsy  
• Preoperative workup as dictated by the NCCN.org prostate cancer guidelines    
• PSA < 15 ng or PSA density < 0.15 ng/ml in patients with a PSA > 15 ng  
 
Design : 
• Pilot study, testing feasibility, safety and tolerabili ty of thermal ablation of focal prostate 
cancer  
• It is anticipated that 15 patients will be accrued for this study  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
3 
 TABLE OF CONTENTS  
Précis  ................................ ................................ ................................ ................................ ..............  2 
TABLE OF CONTENTS  ................................ ................................ ................................ .............  3 
1 INTRODUCTI ON................................ ................................ ................................ .................  7 
1.1 Study Objectives  ................................ ................................ ................................ ..............  7 
1.1.1  Primary Objective(s)  ................................ ................................ ................................ . 7 
1.1.2  Secondary Objective(s):  ................................ ................................ ............................  7 
1.2 Background and Rationale:  ................................ ................................ ..............................  7 
1.2.1  Devi ces Used for MRI -guided LITT  ................................ ................................ ........  9 
1.2.2  PhoTex 15 Diode Laser Series (Cleared for marketing under FDA 510(k): 
K060304)  ................................ ................................ ................................ ..............................  10 
1.2.3  The Visualase® ENVISION Software (Cleared for marketing under FDA 510(k): 
K063505)  ................................ ................................ ................................ ..............................  11 
1.2.4  The Visualase® Thermal Therapy System (Cleared for marketing under FDA 
510(k):  K071328 and K081656)  ................................ ................................ ..........................  12 
1.2.5  IDE Exempt Study  ................................ ................................ ................................ .. 13 
1.3 Laser Safety:  ................................ ................................ ................................ ...................  17 
1.4 Previous Clinical Experience: MR -Guided LITT using Visualase®  .............................  17 
1.5 Post Therapy  Follow -Up and Conclusions:  ................................ ................................ ... 18 
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  ................................ ..................  19 
2.1 Eligibility Criteria  ................................ ................................ ................................ ..........  19 
2.1.1 Inclusion Criteria  ................................ ................................ ................................ .... 19 
2.1.2  Exclusion Criteria  ................................ ................................ ................................ ... 20 
2.2 Screening Evaluation ................................ ................................ ................................ ...... 20 
• A standard prostate biopsy 10 – 12 cores  ................................ ................................ ....... 20 
• MR Image guided prostate biopsy  ................................ ................................ .................  20 
• Potency and incontinence measurement tools – International Prostate Symptom Scoring 
(IPSS), and Sexual Health Inventory for Men (SHIM)  ................................ ........................  20 
• If any other tests have been performed in the evaluation of the subject’s prostate cancer, 
the results will be placed in the subject’s study file.  These may include CXRs, CT scans, 
other imaging modalities, and/or biopsies.  If any of these tests show there is metastatic 
disease, the subject will be excluded from the study.  ................................ ...........................  20 
2.3 Screening and Registration Procedures  ................................ ................................ ..........  21 
2.3.1  Screening Procedures  ................................ ................................ ..............................  21 
2.3.2  Registration Procedure  ................................ ................................ ............................  21 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
4 
 2.4 Baseline Evaluation  ................................ ................................ ................................ ........  21 
3 STUDY IMPLEMENTATION  ................................ ................................ ..........................  22 
3.1 Study Design  ................................ ................................ ................................ ..................  22 
3.2 Laser Fo cal Ablation Procedure  ................................ ................................ .....................  22 
3.2.1  Pre-Procedure Workup ................................ ................................ ............................  22 
3.2.2  Procedure  ................................ ................................ ................................ ................  22 
3.3 Question naires  ................................ ................................ ................................ ................  24 
3.3.1  International Prostate Symptom (Appendix A: IPSS), and the Sexual Health 
Inventory for Men (Appendix B: SHIM)  ................................ ................................ ..............  24 
3.4 Post Procedure Follow Up Schedule:  ................................ ................................ .............  24 
3.4.1  Study Calendar  ................................ ................................ ................................ ........  24 
3.4.2  Follow Up Schedule  ................................ ................................ ................................  24 
3.5 Surgical Guidelines:  ................................ ................................ ................................ ....... 25 
3.6 Radiation Therapy Guidelines: ................................ ................................ .......................  25 
3.7 Criteria for Removal from Protocol interventions and Off Study Criteria  ....................  25 
3.7.1  Criteria for Stopping Laser Procedure  ................................ ................................ .... 25 
3.7.2  Off-Study Criteria  ................................ ................................ ................................ ... 26 
4 Concomitant Medications/Measures: ................................ ................................ ................  26 
5 Biospecimen Collection  ................................ ................................ ................................ ....... 26 
5.1 Tissue Collection, Sample Storage, Tracking and Disposition  ................................ ...... 26 
6 DATA COLLECTION AND EVALUATION  ................................ ................................ . 27 
6.1 Data Collection  ................................ ................................ ................................ ...............  27 
6.2 Response Criteria  ................................ ................................ ................................ ...........  27 
6.3 Toxicity Criteria  ................................ ................................ ................................ .............  28 
7 SAFE TY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN  ................................ ................................ ................................ ................................ ............  28 
7.1 Definitions  ................................ ................................ ................................ ......................  28 
7.1.1  Unanticipated Adverse Device Effect  ................................ ................................ ..... 28 
7.1.2  Serious ................................ ................................ ................................ .....................  29 
7.1.3  Protocol Deviation (NIH Definition)  ................................ ................................ ...... 29 
7.1.4  Non-compliance (NIH Definition)  ................................ ................................ ..........  29 
7.1.5  Unanticipated Problem ................................ ................................ ............................  29 
7.2 NCI-IRB and Clinical Director Reporting  ................................ ................................ ..... 29 
7.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths
 29 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
5 
 7.2.2  NCI-IRB Requirements for PI Reporting at Continuing Review  ...........................  30 
7.2.3  Non Reportable Occurrences secondary to the MRI or prostate biopsy.  ................  30 
7.2.4  NCI-IRB Reporting of Safety Reports  ................................ ................................ .... 30 
7.3 Expedited Adverse Event Reporting to the Manufacturer  ................................ .............  30 
7.4 Data and Safety Monitoring Plan  ................................ ................................ ...................  31 
7.4.1  Principal Investigator /Research Team  ................................ ................................ .... 31 
8 STATISTICAL SECTION  ................................ ................................ ................................ . 31 
9 HUMAN SUBJECTS PROTECTIONS  ................................ ................................ ............  32 
9.1 Rationale For Subject Selection  ................................ ................................ .....................  33 
9.2 Strategies/Procedures for Recruitment  ................................ ................................ ...........  33 
9.3 Justification for Exclusions  ................................ ................................ ............................  33 
9.4 Participation of Children  ................................ ................................ ................................  33 
9.5 Participation of Subjects Unable to Give Consent  ................................ .........................  33 
9.6 Evaluation of Benefits and Risks/Discomforts  ................................ ..............................  34 
9.7 Risks/Benefits Analysis – Monitoring of trial ................................ ................................  34 
9.8 Consent Process and Documentation  ................................ ................................ .............  35 
9.8.1  Telephone consent  ................................ ................................ ................................ .. 36 
10 Appendices  ................................ ................................ ................................ ...........................  37 
10.1  APPENDIX A - International prostate symptom score (IPSS)  ................................ ...... 37 
10.2  APPENDIX B - Sexual Health Inventory for Men  ................................ ........................  38 
10.3  APPENDIX C – Biopsy Criteria illustrations  ................................ ................................  39 
10.4  Appendix D: Study Calendar  ................................ ................................ .........................  42 
11 REFERENCES  ................................ ................................ ................................ ....................  43 
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
6 
 Study Schema  
 
Treatment Schedule  
 
 
Follow up Schema  
 
 Patient referred 
and Identified as 
candidate by 
UOB teamConfirm Elgibility 
and ScheduleConsent and 
Perform 
ProcedurePost Op Day 1
Repeat Imaging, Labs, 
Physical Exam
Discharge HomeDay 1 -7
Foley Catheter 
Removal 
3 months
PE, Labs6 months
PE, Labs, 
Multi -
parametric 
MRI12 months, 
PE, Labs, 
Multi -
parametric 
MRI, Biopsy18 months, 
PE, Labs,24 months, 
PE, Labs, 
Multi -
parametric 
MRI, Biopsy36 months, 
PE, Labs, 
Multi -
parametric 
MRI, Biopsy 
(Optional)
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
7 
 1 INTRODUCTION  
1.1 STUDY OBJECTIVES  
1.1.1 Primary Objective(s)  
• To determine feasibility and safety of magnetic resonance image -guided laser induced 
thermal therapy of biopsy confirmed and MR visible, prostate tumor(s) using the 
Visualase Thermal Therapy System.  
 
1.1.2 Secondary Objective(s):  
• To evaluate tolerability of treatment  
• To determine changes in imaging and biopsy characteristics after thermal ablation of 
localized prostate cancer  
• To obtain preliminary data, as a follow -up to this study, regarding the effect of thermal 
ablation using Visualase on short and long term complication rates  
• To compare Visualase estimates of thermal damage post  contrast MRI images.  
• Determine outcome of laser ablation for treatment of prostate cancer using serial PSA, 
PSA density, changes in imaging, IPSS, and SHIM.  
 
1.2 BACKGROUND AND RATIO NALE:  
Prostate cancer is currently the most commonly diagnosed non -cutaneous cancer of men in 
the United States.  The American Cancer Society currently estimates that 218,000 new cases 
were diagnosed last year and that approximately 27,000 deaths were a result of this disease.1  
The advent of more sensitive PSA (prostate specific a ntigen) testing and advancements in 
ultrasound and MRI imaging, the ability to detect early prostate cancer has increased 
dramatically over past decade, however, our ability to treat earlier disease is still limited.   
Screening with prostate specific anti gen has been associated with a significant risk of 
over diagnosis in detection of prostate cancer that will not become clinically significant in a 
given patient’s lifetime.  A study by Andriole et al in 2009 found that death from prostate cancer 
did not si gnificantly differ in patients who received routine PSA screening versus patients who 
did not receive routine PSA screening.  This study has led researchers to question the relevance 
of PSA screening.  Conversely, in other studies conducted in Europe by Sc hroder et al it was 
found that PSA based screening reduced the rate of death from prostate cancer by 20%.  They 
also reported that they believed that there is a high rate of over diagnosis.2,3   
Patients may choose between expectant management with active surveillance or 
aggressive whole gland treatment which may have significant morbidities.  Many patients have 
indolent prostate cancer that may never foreshorten their lifespan and therefore whole gland 
treatment may “over -treat” these patients.  Unfortunat ely, currently there is no reliable method to 
identify clinically insignificant prostate cancer so many patients are forced to choose whole 
gland therapy.  Therefore, there is a need to investigate focally directed minimally invasive 
treatment for prostate  cancer.  
Active surveillance of prostate cancer with selective, curative, intervention has developed 
as an option for the treatment of clinically localized, low volume prostate cancer to help separate 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
8 
 those patients who are diagnosed with indolent disease  versus those with clinically significant 
disease.  Active surveillance patients are usually diagnosed secondary to PSA screening at earlier 
stages with low levels of disease.  Population epidemiology demonstrates that the majority of 
these patients will n ot develop clinically significant disease within their lifetimes.4  These 
individuals are then followed with routine PSA screening, DRE, and biopsy to monitor for 
progression of disease which may warrant delayed selective curative therapy such as surgery 
and/or irradiation in the event of progression.  Patients with less aggressive disease remain on a 
monitoring protocol until their disease clinically progresses.  Surveillance tools are essential for 
the identification of disease progression.  We have used the criteria set forth by authors to select 
these patients for our trial.5,6  Klotz and colleagues selected patients with PSA < 15 and Gleason 
Score 3+4 or less, these patients were followed and intervention was determined if PSA doubling 
time was less tha n three years or an increase in Gleason score on biopsy , while being followed.  
Core length was not employed in our algorithm due to the fact that MR image guided biopsies 
have statistically significantly longer core length than traditional standard 12 co re biopsies.  
Long term biopsy follow up protocol was a repeat at 1 year then biopsies at 3 -4 year intervals.  
Recent advancements in computer guidance and electromagnetic field generators have 
led to the development of next generation MR Image guide biopsy  systems.   These systems have 
been shown to have improved outcomes in targeting isolated prostate cancers for biopsy.7  As a 
result, several minimally invasive thermal ablation methods, most prominently cryotherapy8,9 and 
high-intensity focused ultrasound  (HIFU) 9, 10 have been developed and are currently being 
evaluated.  Laser -induced interstitial thermal therapy (LITT) is a novel form of controlled, 
targeted thermal ablation that offers imaging and t argeting of prostate tissue superior to that of 
either cryotherapy or HIFU. Improvements in the design of medical laser systems used for 
thermal coagulation of tissue, which include the development of water -cooled applicators to 
facilitate higher powers ca pable of rapidly creating larger ablation zones without tissue charring 
and the development of high -power diode laser sources, have made modern systems smaller, 
more portable, more powerful, and less expensive than previous generations of medical laser 
systems.  
Because LITT is magnetic resonance (MR) compatible, it confers an imaging advantage 
over other surgical or ablation techniques that utilize trans -rectal ultrasound to target and monitor 
treatment.11  MR imaging provides excellent soft -tissue contrast and three -dimensional (3D) 
anatomical imaging in any arbitrary plane, which can help to improve treatment planning and 
targeting.12, 13  Additionally, MR -based temperature monitoring allows real -time feedback during 
MRI -guided thermal therapy14 and, in the ca se of thermal therapy, and post -treatment imaging 
can be used to verify treatment delivery.15 Because MR images clearly depict the prostate 
anatomy and the surrounding critical structures, MR imaging has been incorporated into 
planning for external -beam rad iotherapy and brachytherapy of the prostate.14   In addition to 
these basic features, recently developed/emerging MR technologies, such as MR spectroscopy, 
MR diffusion imaging, and dynamic contrast -enhanced MR imaging, are promising technologies 
that may be used to identify regions of disease in the prostate and better target therapy, 
particularly as high -field scanners (3.0T) become available.12,13  Clearly, there is a potential role 
for MR -guided ablation technology in the prostate.  
Our in house unpublished data with Choyke and colleagues r eported on the correlation of 
multi -parametric MR with whole mount pathology.  Positive predictive value of T2W MRI, 
ADC maps of DW MRI, MRS, DCE MRI were 0.7, 0.73, 0.93, 0.86, respectively in the overall 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
9 
 prostate gland. The sensitivities of MRI sequences  were significantly higher for tumors that were 
>5mm in diameter as compared with those ≤5mm, as well as for tumors with higher Gleason 
scores (>7) (p<0.05 for all pair wise comparisons). Multi -parametric analysis reveals that 
multiple MRI sequences provid ed significantly higher predictive value (all four modalities 
positive PPV~98% and NPV of 98%) than each single MRI sequence and some doublet MRI 
sequences (p<0.01).  
In this study, we propose to evaluate a novel, thermal therapy and feedback system 
(Visualase® Thermal Therapy System) for the treatment of biopsy confirmed and MR image -
able prostate cancer lesions.  This system includes the FDA -cleared Visualase Cooled Laser 
Applicator System (VCLAS), which allows delivery of laser energy while the pat ient is being 
imaged by an MRI unit.  The Visualase® System works via real -time MR thermal imaging 
(MRTI) to provide information on the thermal dose delivered to the target, resulting in a more 
precise and controlled delivery which has heretofore not been possible with previous non -image 
guided laser technology.  We hypothesize that the Visualase system can be integrated into a 
practical and feasible treatment paradigm for focal prostate cancer therapy.  
1.2.1 Devices Used for MRI -guided LITT  
Visualase, Inc. curre ntly markets all of the FDA 510(k) cleared medical devices which will be 
used in these studies.  These devices are currently manufactured by the original developer of the 
technology, BioTex, Inc., Visualase, Inc.  The Center for Interventional Oncology / N ational 
Institutes of Health owns the device.  Each device is listed below:  
 Visualase Cooled Laser Application System  
 PhoTex 15 Diode Laser Series 980,810,940  
 Visualase ENVISION Workstation  
 Visualase Thermal Therapy System (combination of three FDA -cleared  
devices)  
Each of the 510(k) cleared devices will be used according to its intended use and indicated 
statement. The devices will be used for magnetic resonance thermal imaging -guided laser 
induced thermal therapy in soft tissue prostate lesions.  
Visualase Cooled Laser Applicator System (VCLAS) (Cleared for marketing under FDA 510(k): 
K053087)  
The Visualase Cooled Laser Application System (VCLAS) family consists of three (3) 
components, the Laser Diffusing Fiber (LDF), Cooling Catheter System (CCS)  (Figure 1), and 
Bare Tip Fiber (BTF).  The LDF and BTF transmit laser energy to the tissue situated at their 
distal regions. The LDF comprises a standard silica fiber optic cable affixed with a diffusing tip 
assembly. The diffusing tip assembly comprises a plastic tube that is filled with a transparent 
matrix in which light dispersing particles are embedded. The distal end of the tube is sealed with 
a higher concentration of scattering particles in a conical structure to prevent significant forward 
transmi ssion of energy. The LDF may be used with a cooling catheter, in particular the 
compatible CCS but such a catheter is not required. The CCS can be employed with or with or 
without coolant flow. The use of coolant flow provides cooling for the surfaces of t he CCS in 
contact with both the tissue and the LDF. The BTF is comprised of a standard silica fiber optic 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
10 
 cable identical to fiber optic used in the LDF. The distal end of the BTF is terminated in a flat, 
polished face and is designed for use in both conta ct and non -contact applications. The LDF and 
CCS are indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or 
thermal therapy in medicine and surgery in cardiovascular thoracic surgery (excluding the heart 
and the vessels  of the pericardial sac), dermatology, ear -nose-throat surgery, gastroenterology, 
general surgery, gynecology, head and neck surgery, neurosurgery, plastic surgery, 
pulmonology, radiology, and urology. The BTF is intended for use in vaporization, cutting, 
ablation and coagulation of soft tissues with or without scopes or hand pieces, for contact or non -
contact surgery in cardiovascular thoracic surgery, dermatology, ear -nose-throat surgery, 
gastroenterology, general surgery, gynecology, head and neck surger y, neurosurgery, plastic 
surgery, pulmonology, radiology, and urology.  
1.2.2 PhoTex 15 Diode Laser Series (Cleared for marketing under FDA 510(k): K060304)  
The PhoTex 15 Diode Laser Series (Figure 2) are diode lasers emitting radiation in either a 
continuous -wave or pulsed -mode in the infrared range at one of the following wavelengths: 
980nm, 810nm, and 940nm. The PhoTex 15 Diode Laser Series provides a means for cutting, 
coagulation, and vaporization of tissue using a compatible fiber optic delivery accessory.         
The laser is compatible with any fiber optic delivery accessory terminated with a standard 
SMA905 connector whose core fiber diameter is 400 micron or larger with a numerical aperture 
of at least .37.  The PhoTex 15 Diode Laser Series is indicated for use in surgical applications 
requiring  the ablation, 
vaporization, excision, 
incision, and coagulation of 
soft tissue in areas of surgery 
including: gastroenterology, 
general surgery, plastic 
surgery, genitourinary, 
gynecology, neurosurgery, 
otolaryngology, head and 
neck, orthopedics, 
ophthalm ology, 
pulmonology, and thoracic surgery.  
 
 
 Figure 1:  (Above Left) Visualase Cooled Laser Applicator System.  Includes 1.65mm Cooling Catheter and Diffusing Tip Laser Fiber.   
Figure 2:  (Above Right) PhoTex15 Laser.  15W, 980nm Fiber Coupled Diode Laser.  
 
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
11 
 1.2.3 The Visualase® ENVISION Software (Cleared for marketing under FDA 510(k): 
K063505)  
The Visualase® ENVISION platform (Figure 3) consists of a PC -based Linux workstation 
running the ENVISION software tools in an X-windows environment.  The device uses a 
standard Ethernet connection to retrieve image data files from a compatible MRI scanner host. 
The images may be retrieved as soon as they have been stored on 
the MRI host, facilitating near real -time analysis of dy namic MRI 
data.  The Visualase ENVISION software tools perform the 
following three (3) functions:  
 Image Transport  
 Image Processing  
 Data Display  
Figure 3 :  Visualase® ENVISION Software User Interface.  Real -time thermal (left) 
and damage (middle) images are  displayed with a high -resolution pre -therapy planning 
image (right).  Targets and limit temperatures are set by “clicking” on any image. Users 
can see temperature at any point, make measurements, and control most other system 
functionality through this in terface . 
 
 
The image transport tools negotiate communication with the MRI scanner host, determine the 
availability of images, facilitate retrieval of image files, facilitate local storage of image files, 
and notify Image processing tools of new data.  The Image processing tools extract relevant data 
from available MR images and update data analysis information.  The Data display tools on the 
Envision user interface (Figure 4) provide visualization and facilitate manipulation of the data 
extracted by the Ima ge processing tools.  Data may be processed to display dynamic changes in 
voxel intensity as a function of image acquisition.  Such analysis is useful in analyzing the 
uptake and washout of MR contrast agents and can be useful for discrimination of tissue type or 
state.  When data from compatible sequences is available, images may also be processed to 
extract the complex phase angle of voxels as a function of image acquisition.  Using proton 
resonance frequency (PRF) shift analysis and image subtraction, ch anges in complex phase angle 
may be related back to relative changes in temperature during the study.  The Visualase 
ENVISION workstation is intended to retrieve, store, process, and display temporally dynamic 
magnetic resonance (MR) data from compatible s canners.  The software is capable of analyzing 
either temporal changes in image intensity as is useful in, for example, dynamic contrast 
enhancement studies, or temporal changes in complex phase image data as is useful in, for 
example, phase contrast angio graphy or in determinations of dynamic phase changes related to 
temperature changes in soft tissues.  The image data may be manipulated and viewed in a 
number of different ways and the value of data at certain selected points may be monitored and 
or displa yed over time.  When interpreted by a trained physician, this device provides 
information that may be useful in the determination or assessment of a diagnosis, intervention, or 
course of treatment.  
 
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
12 
 1.2.4 The Visualase® Thermal Therapy System (Cleared for marke ting under FDA 
510(k):  K071328 and K081656)  
The Visualase Thermal Therapy System (Figure 4) is indicated for use to necrotize or coagulate 
soft tissue through interstitial irradiation or thermal therapy under magnetic resonance imaging 
(MRI) guidance in m edicine and surgery in cardiovascular thoracic surgery (excluding the heart 
and the vessels in the pericardial sac), dermatology, ear -nose-throat surgery, gastroenterology, 
general surgery, gynecology, head and neck surgery,  neurosurgery, plastic surgery,  orthopedics, 
pulmonology, radiology, and urology, for wavelengths 800nm through 1064nm.  
When therapy is performed under MRI guidance, and when data from compatible MRI 
sequences is available, the Visualase system can process images to determine relative c hanges in 
tissue temperature during therapy. The image data may be manipulated and viewed in a number 
of different ways, and the values of data at certain selected points may be monitored and/or 
displayed over time.   When interpreted by a trained physicia n, this device provides information 
that may be useful in the determination or assessment of thermal therapy. Patient management 
decisions should not be made solely on the basis of Visualase analysis.  
The Visualase Thermal Therapy System is in effect a com bination of the first three devices 
described and is used for performing Laser Induced Thermal Therapy to destroy malignant or 
unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the 
tissue.  The Visualase Thermal The rapy System will be used in this study according to 
indications previously cleared for marketing by the FDA.  An MRI technique called Magnetic 
Resonance Temperature Imaging is used to collect temperature -sensitive parameters throughout 
the imaged volume. D uring tumor ablation, MRTI data will be collected and analyzed to display 
real-time tissue temperatures and an estimate of thermal ablation zone size.  Immediately after 
completion of therapy, MRI (including dynamic contrast T1, T2, and diffusion -weighted 
imaging) will be used to confirm the achieved thermal ablation zone size.    
   
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
13 
 Figure 4 : Visualase® Thermal Therapy System.  The Visualase Thermal Therapy system is a combination of the 
VCLAS applicator, the PhoTex15 Laser, the Envision Workstation and a  FDA cleared perfusion pump.  The 
Visualase Thermal Therapy system has been cleared for marketing by the U.S. FDA.  
1.2.5 IDE Exempt  Study  
We have identified this investigation as IDE exempt under 21 CFR Part 812.2(c) .  All 
devices used on the study are FDA approved/cleared , are being used as indicated and were not 
regulated as devices before the enactment of the Medical Device Amendments .   
  
1.2.5.1  Preliminary Human Studies of Visualase Therapy in the Prostate  
Four patients underwent MRI guided laser ablation of t he prostate using the Visualase system 
under a treat and resect protocol at the University of Toronto.  No patients experienced 
complications from the ablation or post ablation prostatectomy.  A personal communication with 
the lead investigator: to ask the  question regarding difficulty of post ablation prostatectomy, he 
reports that the ablation did not increase the difficulty or complication associated with 
performing a post focal ablation prostatectomy.  Comparing the MRI predicted ablation zone 
with whol e mount histopathology showed a direct correlation.16 
1.2.5.2  Preliminary Animal Studies of Visualase Therapy in the Prostate  
In seven adult canines,  a total of 11 ablations, 9 in normal tissue sites and 2 in tumor sites 
(immuno suppressed tumor model), were perfo rmed under MR guidance.  Imaging was 
performed on a clinical 1.5 -T MR scanner (Excite HD, GE Healthcare, Waukesha, WI).   
Applicators were surgically inserted into the prostate of the 2 tumor -inoculated dogs via a 
laparotomy procedure.  In the remaining 5 dogs, an MR -compatible perineal template grid with 
MR-visible markers was used to facilitate a transperineal approach (Figure 5).  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
14 
 For treatment planning, the Visualase software was used to read the images from the MRI 
scanner and to select critical tempe rature control points.  A high temperature control point (90ºC -
95 ºC threshold) was placed near the applicator -tissue interface to minimize the possibility of 
deleterious high -temperature effects (char formation, vaporization, and cavitation), which would 
limit the size of the ablation zone created and could possibly damage the applicator.  If the 
temperature exceeded this preset 
limit temperature of 90ºC during 
treatment, the laser was shut off, 
the tissue allowed to cool, and 
then treatment resumed until the 
full lesion was generated.  Low 
temperature control points (45ºC -
50ºC threshold) were set near 
critical structures, such as the 
urethra, in order to avoid damage 
to these tissues.  Laser exposure 
times and power levels were 
controlled using the worksta tion 
interface during treatment 
delivery.   
Figure 5.  Planning of applicator 
placement with template guidance.  a) 
Diagram of the perineal template 
demonstrating the location of the 3 MR -
visible markers for registration (left) and 
the actual template on th e perineum with 
2 laser applicators placed in the prostate 
(right).  b) Appearance of the 3 MR -
visible markers on 3D T1 -weighted 
images. c) An image of the prostate with 
(right) and without (left) the template 
grid overlay.  
During treatment, temperature changes were monitored in real time using the temperature -
dependent proton resonance frequency shift technique and acquired phase -sensitive images every 
5 seconds using a gradient recalled echo pulse sequence.  Tissue damage estimates from the 
Visualase so ftware are superimposed on the magnitude MR anatomical images and displayed in 
real time to aid in treatment decision -making.  
Fixed prostate specimens were sliced along planes that were nearly congruent with the treatment 
plan for histopathologic analysis where a trained veterinary pathologist independently identified 
the borders of thermal necrosis for all ablation zones.  
The mean width was 13.7 mm ± 1.3 mm (range 11.4 –15.5 mm) and the mean length was 19.0 
mm ± 4.2 mm (range 12.4 –26.7 mm) using single and  compound exposures with power levels 
ranging from 4W to 14 W and maximum single exposures of up to 240 seconds (Table 1).  The 
average exposure time per site was 158 seconds, and the average energy delivered was 995 J.  
a)
b)
c)
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
15 
 Using the workstation software for monitoring, maximum tissue temperatures were maintained 
below 90ºC.  Temperatures at the margins of the ablated zone ranged between 54ºC and 60ºC.  
Temperature maps were converted to thermal dose via the Arrhenius relation and displayed in 
real time (Figur e 6).  Measurements of the area of Arrhenius -estimated tissue damage were 
correlated with the outer rim of enhancement on 3D T1 -weighted post -contrast images in the 
same plane to determine the degree of agreement.  An excellent correlation between these 
measurements was observed (Pearson’s R2 = 0.94, Figure 7).  As desired, the slope of the 
regression line was close to unity (m = 0.96) and the intercept (b = 8.44 mm2) was small relative 
to the smallest ablation zone measured (115 mm2).  The mean percentage error in the Arrhenius 
measurement versus the T1 measurement was -0.28% ± 7.6%, with an absolute error of 5.5% ± 
4.9%.  
Table 1. Summary of MR -guided LITT exposure times and size of ablation zones generated in a 
cTVT canine prostate model  
Subject  Lobe  Site† Length  
(mm)  Width  
(mm)  Power  
(W) Time  
(sec)  Tot. 
time 
(sec)  Energy  
(J) 
1 R A 12.4 13.8 (4, 4)‡ (114, 121)  235 940 
1 L* A 
B 21.2 13.4 (4, 4)  
6 (182, 121)  
59 362 1562  
2 R* A 
B 
C 26.7 12.9 (4, 6)  
(6, 6)  
(4, 4)  (121, 72)  
(39, 66)  
(106, 120)  524 2450  
3 R A 23.2 14.6 14.3 40 40 572 
4 R A 17.7 12.5 12 63 63 756 
4 L A 17.5 11.4 (12, 11.3, 6, 6)  (37, 37, 243, 190)  507 3460  
5 R A 
B 22.8 15.4 12.8 
6.4 29 
202 231 1664  
5 L A 19.1 14.9 6.4 71 71 462 
6 R A 16.5 15.5 (6, 12)  (32, 104)  136 1440  
6 L A 13.2 12.2 (6, 12)  (33, 74)  107 1086  
7 R A 19.2 14.0 6 90 90 540 
*Exposures made in cTVT tissue.  
†Different sites treated by pulling fiber back in applicator.  
‡In cases where multiple exposures were performed to generate a larger/longer ablation zone, the 
power and  exposure time are expressed as (Exposure 1, Exposure 2, …).  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
16 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.   MR-guided LITT in a canine prostate model.  MR temperature imaging from the Visualase workstation displays the temperature 
changes in the prostate in real time (a), are used to estimate and display the TNZ (b), which correlated well with the outer edge o f the ring of 
edema seen surrounding a non -perfused region of tissue on post -treatment (less than 20 minutes) 3D T1 -weighted contrast -enhanced images (c).  
Dotted green lines show the edges of estimated tissue damage projected onto both images (b and c) fo r visual correlation.  The images from (c) 
were reformatted (d) to better match the actual slices taken from photographic pathology and H&E histology, where the ablatio n zone is 
contained inside the red reference line (e).  The histological damage demonstr ated the classic presentation of thermal necrosis as described in the 
text, with a very narrow region of transition between normal and necrotic cells (f).  Despite slight through -plane refraction and approximated slice 
orientations, excellent agreement was  generally seen.  
 
Figure  7.  Three -dimensional T1 -weighted post -contrast 
measurements of LITT -induced ablation size (measured from the 
outer edge of edema) versus the Arrhenius -estimated tissue damage 
based on MR demonstrated excellent correlation.  Linea r least -
squares regression indicates a slope near unity and a bias much 
smaller than the area of the smallest ablation zone measured . 
 
 
 
 
 
 
 
 
 
(a) (b) (c)
(d) (e) (f)
y = 0.96x + 8.44
R2 = 0.94
70120170220270320
70 120 170 220 270 320Arrhenius Estimated Size (mm2)T1-W Post -Contrast Size (mm2)
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
17 
  
1.3 LASER SAFETY:  
The NIH approved laser safety protocol will be used in reference to the Visualase laser.  Persons 
using the laser will be trained on safety, as well as use.  There are no exposed beams, the door 
will be placarded, and goggles will be available.   Please se e accompanying documents for Laser 
Safety at the NIH.  
Point of Contact of Laser Safety:  
Arvin George, M.D., NCI/UOB  
 
1.4 PREVIOUS CLINICAL EX PERIENCE: MR -GUIDED LITT USING VISUALASE ® 
The majority of the clinical experience with Visualase has been in brain tu mor applications.  To 
date over 40 treatments have been performed clinically without any procedural complications or 
notable adverse events.  Additionally the system has been used clinically for treatments in bone 
(n=5), liver (n=8), thyroid (n=2) and pros tatic bed for local recurrence (n=1).   Figure 8 below 
shows images from a patient that was treated for a local recurrence in the prostatic bed after 
prostatectomy.  A urethral cooling catheter was placed and chilled water was circulated during 
therapy.  T wo applicators were placed into the tumor using the MR -compatible trans -perineal 
guide template and planning software.  The procedure was completed without complication and 
the patient’s Foley catheter was removed after 1 day.  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
18 
  
1.5 POST THERAPY FOLLOW -UP AND CONCLUSIONS:  
Clinical results thus far from using the Visualase Thermal Therapy System have been positive in 
all regards.  Based on the clinical results to date using the  system we can summarize the results 
as follows:  
 In all procedures patients have recovered after therapy without 
complication  
 There were no complaints of pain during therapy or post operatively.   
 
 
 
 
 
  
 
Thermal Image  
 Estimated Damage  
 Thermal Image  
 Estimated Damage  
Region of Interest  
 Region of Interest  
Figure  8.  Thermal and estimated damage images from selected 
time points during Visualase clinical ablation of local prostate 
cancer recurrence after prostatectomy.  Note, the noticeable lower 
temperatures maintained within and around the urethra from the 
cooling ca theter.   
1 
2 
4 
3 
5 
6 
7 
Final Damage Area  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
19 
  All patients have been discharged from the hospital within 24 hrs after the 
procedure, with the exception of one patient who was kept for 48 hours due to 
additional unrelated care.   
 In all cases, the Visualase predicted lesion size agreed with post -treatm ent 
MRI -based assessment.   
 Visualase guidance has allowed effective treatment of brain, bone, liver, 
and prostate tumors and avoidance of critical neural structures during therapy.     
 Follow -up imaging of up to 18 months has demonstrated destruction of 
tumor masses and no signs of active tumor present in ablated areas based on 
contrast MRI studies.   
 No significant edema or mass effect has resulted from thermal treatments 
when patients were maintained on steroids prior to and for short periods after 
thera py. 
2 ELIGIBILITY ASSESSME NT AND ENROLLMENT  
2.1 ELIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria  
2.1.1.1  Men greater than 18 years of age  
2.1.1.2  Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR 
imaging  
2.1.1.3  Prostate cancer is diagnosed by transrectal u ltrasound guided standard 12 core biopsy or 
MR image guided biopsies (See Appendix C)  
2.1.1.3.1  Gleason Score < 7 (3+4), < 3 cores positive in a standard 12 core biopsy or <4 cores 
positive on MR image guided biopsy where in 2 cores are taken from each of the two 
MRI target lesions  
2.1.1.3.2  If the standard biopsy cores are positive, they must be from the same location in the 
prostate as MR Lesion was biopsied and proven to be cancer.  (Left / Right, Base, Mid 
Gland, Apex).   
2.1.1.4  MRI obtained within 6 months of ablation  
2.1.1.5  Metastati c Disease work up as per NCCN guidelines ( www.nccn.org ) – Bone scan 
indicated to r/o metastatic disease if [clinical T1 and PSA > 20 or T2 and PSA > 10]       
2.1.1.6  PSA < 15 ng/ml or PSA density < 0.15 ng/ml2 in patients with a PSA > 15 ng/ml  
2.1.1.7  The patient has given written informed consent after the nature of the study and 
alternative treatment options have been explained.  
2.1.1.8  Patients who present with local recurrence or residual tumor after prostate cancer 
treatment which is visi ble on MRI.  
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
20 
 2.1.2 Exclusion Criteria  
2.1.2.1  The presence of 3 or more MR Visible lesions positive on biopsy  
2.1.2.2  The presence of extra capsular, seminal vesical invasion or metastatic disease.  
2.1.2.3  Patient is unable to tolerate MRI (foreign body, i.e. pacemaker or other implanted 
device; claustrophobia; inability to tolerate rectal coil; etc…)  
2.1.2.4  Patient with inability to follow up  
2.1.2.5  Acute urinary tract infection  
2.1.2.6  Lower urinary tract symptoms defined by a International Prostate symptom score 
(IPSS) > 20  
2.1.2.7  Patients with renal insufficiency with an estimated glomerular filtration (EGF) <= 30 
are excluded, due to they will not be able to undergo gadolinium enhance MRI.  
2.1.2.8  Patients with Uncontrolled Coagulopathies  who are at increased risk of bleeding.  
2.1.2.9  Altered mental status preventing consent or answering questions during conduct of the 
trial will be excluded for safety purposes.  
2.1.2.10  Other serious illnesses according to the PI: involving the cardiac, respiratory, CNS, 
renal or hepatic organ systems, which would preclude study completion or impede the 
determination of causality of any complications experienced during the conduct of this 
study.  
2.1.2.11  A Standard 12 core biopsy positive for cancer with no corresponding MR target ed 
lesion positive for cancer in the same general region of the prostate (Right Apex, Right 
Mid Gland, Right Base, Left Base, Left Mid Gland, Left Apex)   
2.2 SCREENING EVALUATION  
 
The following studies will be completed within 30 days of study entry, unless ot herwise 
specified.  
• Complete History and Physical exam, including a digital rectal exam, including vital 
signs  
• Laboratory Testi ng: CBC, Chem 7, PT/PTT/INR and urine laboratory (urinalysis, 
culture) determinations; PSA blood level, Comprehensive Metabolic Pa nel (SMA -20) 
• Metastatic disease work up as indicated by NCCN guidelines 
(http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf ). 
• A standard prostate biopsy 10 – 12 cores  
• MR Image guided prostate biopsy  
• Potency and incontinence measurement tools – International Prostate Symptom Scoring 
(IPSS), and Sexual Health Inventory for Men (SHIM)  
• If any other tests have been performed in the evaluation of the subject’s prostate cancer, 
the results will be placed in the subject’s study file. These may include CXRs, CT scans, 
other imaging modalities, and/or biopsies.  If any of these tests show there is metastatic 
disease, the subject will be excluded from the study.  
 
 
 
 
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
21 
  
 
2.3 SCREENING AND REGIST RATION PROCEDURES  
2.3.1 Screening Procedures  
Individual subjects will be enrolled and evaluated in the outpatient clinic at the Clinical Center of 
the National Institutes of Health.  It is possible that the initial evaluation may occur while a 
subject is a Clinical Center in -patient.  An introductory  telephone conversation with the subject 
may occur with one of the UOB research nurses or associate investigators.  At that time, a brief 
description of the research study will be provided.  The subject’s medical records including a 
clinical history, labor atory and x -ray findings, pathologic tissue and physical assessment may be 
obtained from the referring medical provider or the patient’s primary health care provider.  These 
records will be reviewed by one or more Associate Investigators for acceptance of the subject 
into the study protocol. Tissue received from off -site facilities may be analyzed by the NCI 
Laboratory of Pathology.  If accepted and the subject agrees to participate, arrangements for the 
initial clinic visit will be made by a research nurse .  
It is estimated that each subject traveling to Bethesda from a distance will spend approximately 
1-4 days undergoing outpatient clinical evaluations in the Clinical Center.  NIH subjects will stay 
at a local hotel or the Guest House.  Affected patients may require hospitalization for treatment 
of tumors and procurement of tissue.  These procedures will be standard of care surgical 
treatment under an IRB approved tissue procurement protocol.  Any experimental forms of 
therapy will only be conducted on a s eparate protocol.  
For patients living within 115 miles of Bethesda, outpatient studies will be scheduled at the 
patient’s convenience with anticipated Clinical Center outpatient tests occurring over an elapsed 
period of several weeks.   
Due to the nature of this study attempts at randomization will not be possible.  
2.3.2 Registration Procedure  
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) 
within 24 hours of signing consent.  A registration Eligibility Checklist f rom the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to:  NCI Central Registration Office ncicentralregistration -l@mail.nih.gov .  
Verification of Registration will be forwarded electronically via e -mail to the research team. A 
recorder is available during non -working hours.  
 
2.4 BASELINE EVALUATION  
The followi ng baseline measurements will be performed upon enrollment on the protocol:  
1) Physical Examination  
2) Laboratory Evaluation: CBC, Chem 7, PT/PTT/INR, and PSA  
3) Urinalysis and culture  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
22 
  
3 STUDY IMPLEMENTATION  
3.1 STUDY DESIGN  
This is an open, single -center, non-randomized, pilot study.  Fifteen (15) subjects with biopsy 
proven and MRI -imageable localized prostate cancer meeting all other entry criteria will be 
admitted to the study.  Eligible subjects will undergo MR -thermal image guided laser ablation of 
all biopsy proven areas of prostate cancer using one or multiple laser probes during a single 
procedure lasting approximately two hours in duration.  Following completion of the thermal 
treatment, subjects will be evaluated with a physical examination and PSA  test. Subjects will be 
asked to return for PSA determinations and physical exam, biopsies and imaging following 
treatment.  It is anticipated that patient accrual into this study will be completed in approximately 
6 months.  Each subject will participate in the study for approximately 3 years following the 
thermal treatment.  
3.2 LASER FOCAL ABLATION  PROCEDURE  
3.2.1 Pre-Procedure Workup  
The MRI obtained on the pre -procedure workup will be evaluated by an NIH urologic radiologist 
(P Choyke MD or his designee) and susp icious areas for cancer will be marked for biopsy.  The 
patient will undergo a standard transrectal ultrasound (TRUS) 12 -core prostate needle biopsy and 
biopsy of any MR suspicious lesions.  The biopsies will be fixed and read.  The target area of 
laser ab lation will be chosen from our biopsy data.  All biopsies obtained in this study will be 
read by the same NCI urologic pathologist (M Merino MD or her designee) for consistency and 
report percent core length for each biopsy and percent of primary and secon dary Gleason score 
features.  If diffuse disease is detected the patient will be excluded from the protocol as defined 
in section 2.1.2.  
3.2.2 Procedure  
3.2.2.1  Step 1: Study Treatment Procedures (Setup)  
After the subject has completed all baseline evaluations he will b e scheduled for Visualase 
Therapy.  The subject will be placed on a MRI gantry table and routine general anesthesia will be 
delivered by a registered anesthesiologist.  Once induction is achieved and permission to proceed 
is given by the anesthesiologist t he subject will be prepared and draped in the supine position.  A 
urethral cooling catheter will be inserted and an MR -compatible perineal guide template will be 
placed on the perineum between the patients legs.  Axial MRI scans (1.5 T Philips MR) 
containi ng both the prostate anatomy and the perineal guide template will be acquired and 
software on the Visualase System used to register the template to the anatomy.   
Targets (previously assessed by NCI radiologist) in the prostate will be selected using the 
Visualase Plan software which provides the appropriate guide hole and distance to insert laser 
applicators.  A 14ga titanium introducer system will be used to place Teflon catheters into the 
target area.  One 17Ga laser applicator will be placed though each  Teflon catheter and into the 
area targeted for treatment.  The course and location of the laser applicators can be assessed by 
acquiring MR -images prior to therapy.   
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
23 
 3.2.2.2  Step 2: Thermal Therapy – DAY 0  
The patient will remain positioned within the MRI unit f or the duration of therapy.  An imaging 
plane containing the applicator will be chosen, and a T1 planning image will be acquired.  After 
loading the planning image into the Visualase System, temperature sensitive fast RF -spoiled 
gradient recalled echo (FSP GRE) images will be acquired repeatedly on the MRI and transferred 
in real -time to the Visualase® workstation for analysis.  After establishment of baseline, the laser 
will be activated at a reduced power level insufficient to cause thermal injury. This in termediary 
step is performed to verify proper placement of the applicator and proper operation of thermal 
imaging.  Subsequent to this test pulse, laser treatment will be initiated.  A single lesion will 
require between 30 -240 seconds of laser -radiation at  a power level of 6 -15 watts. Typically, 
imaging will continue for approximately 30 -60 seconds after cessation of laser irradiation in 
order to fully visualize cooling and return to baseline.   During each laser treatment, temperatures 
of the rectal wall a nd urethral structures closest to the area of prostate being treated will be 
monitored using the Visualase software.  If the temperatures at either point reach 45 C or higher, 
the system will automatically terminate laser delivery.  Thermal therapy treatment may resume 
after the temperature of the rectum and urethra has dropped to 40 C.  If additional treatments are 
required, the laser applicator will be repositioned or a separate laser applicator will be connected 
to the system and the above imaging /application procedures will be repeated.  At the end of all 
laser treatments, post treatment MR images (including dynamic contrast -enhanced T1 as well as 
T2 weighted images) will be acquired for determination of the effective treatment region.   
Following  thermal treatment and after removal of urethral cooling catheter, a Foley -type urethral 
catheter will be placed and remain in place for 1 to 7 days following the thermal treatment. An 
anti-spasmodic medication to prevent bladder spasm should be administer ed following the 
thermal therapy treatment. Antibiotic prophylaxis will be administered 30 minutes prior to the 
procedure and given according to AUA antimicrobial Guidelines.17  This should consist of 
antibiotics preoperatively and peri -urethral catheter re moval.  
 
3.2.2.3  Step 3:  RECOVERY:  
Subjects will recover in the PACU under anesthesia surveillance.  Subjects are to be 
discharged home the following day.  
3.2.2.4  Step 4: Post -Treatment Evaluation Procedures  
24 hours following the thermal therapy treatment, the following  study procedures will be 
performed:  
• A complete physical examination, including a DRE , when indicated.  
• Multi -parametric MR of the prostate  
3.2.2.5  Step 5: Removal of Foley Catheter  
One to seven days following the thermal therapy treatment, the subject should retu rn to 
have the foley removed.  Antibiotics will be administered orally the day before, the day 
of and the day after the Foley is removed.   
Foley catheter removed and ability to urinate evaluated according to standard procedures. 
If the investigator determines that the subject is experiencing urinary retention so that the 
catheter cannot be removed at this visit, this information will be recor ded on the case 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
24 
 report form. The investigator will determine when the subject should return for further 
evaluation. A record will be kept of each subsequent attempt to remove the catheter and 
the outcome of that attempt. The date the catheter is finally re moved as well as any 
complications and/or medications administered will be recorded on the case report form.  
3.3 QUESTIONNAIRES  
3.3.1 International Prostate Symptom (Appendix A: IPSS), and the Sexual Health 
Inventory for Men (Appendix B: SHIM)  
Patients with prostate  cancer may be asked to complete the International Prostate Symptom 
(Appendix A: IPSS), and the Sexual Health Inventory for Men (Appendix B: SHIM) 
questionnaires.  These validated tools assess issues in prostate cancer patients.   Questionnaires 
to be admi nistered at all office follow up visits as described in Appendix D: Study Calendar.  
3.4 POST PROCEDURE FOLLO W UP SCHEDULE:  
3.4.1 Study Calendar  
See Appendix D  
 
3.4.2 Follow Up Schedule  
3.4.2.1  Repeat Imaging using Multiparametric MRI  (Scans can be obtained within +/ - 1 month 
of the target time table)  
3.4.2.1.1  Day 0 –MR immediately prior to ablation (localize targets areas) and post ablation 
with gadolinium (to assess ablated zone)  
3.4.2.1.2  Day 1 post operatively  
3.4.2.1.3  6 months  
3.4.2.1.4  12 months, and  
3.4.2.1.5  24 months, and 36 months after the treatment.   
3.4.2.1.6  Then yearly  thereafter for evaluation under the care of the local medical physician, but 
data will not be collected on this study (this utilizes the Cleveland clinic post operative 
imaging protocol used in kidney cancer).18   
 
3.4.2.2  Clinic Visits will occur at 3, 6, and 12,  18, 24 months post procedure, then yearly 
thereafter for a total of 3 years, and include:  
3.4.2.2.1  History and physical exam with DRE  
3.4.2.2.2  Laboratory evaluations including CBC, Chem 7, PT/PTT/INR and urine laboratory 
(urinalysis, culture) determinations, PSA blood test s 
3.4.2.2.3  Completion of IPSS, and SHIM evaluations  
 
3.4.2.3  Prostate biopsy follow up:  (Standard and MR Image guided biopsy of treated targets 
and any new targets) at 12, 24 months.  Further biopsies at 36 months are optional and 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
25 
 additional biopsies as clinically indica ted. (Biopsies can be obtained within +/ - 1 month 
of the target time table)  
3.4.2.4  Clinically Indicated Radiologic Studies  
3.4.2.4.1  MRI of Prostate – if there is concern that there may be a change in size or possible 
extra -capsular extension of the p rostate cancer in question or a concern for 
hemorrhage or other physiologic change in the nature of the gland.  
3.4.2.4.2  MRI of Brain – if there is concern for spread of cancer to the brain.  
3.4.2.4.3  Bone Scan – if there is a concern for metastatic spread of the prostate cancer to the 
skeleto n  
3.4.2.4.4  CT of Chest/Abdomen/Pelvis – if there is a concern for metastatic spread of the 
prostate cancer to organs or other viscera.  
3.4.2.4.5  Transrectal Ultrasound Guided Biopsy – for evaluation of area of laser ablation as well 
as to evaluate the possible reoccurrence o f prostate cancer.  
3.4.2.4.6  Urodynamic Studies – these studies may be warranted in instances where patient 
experienced dysfunctional voiding.  
3.4.2.5  Unscheduled Visits  
Unscheduled visits may be necessary during the conduct of the study.  At each visit, the subject 
will b e instructed to contact the investigator if he experiences new or worsened urologic 
conditions or complications.  The investigator may request that the subject be seen for a non -
scheduled visit.  The specific findings from this visit will be recorded in th e subject’s medical 
record and appropriate data (i.e., complications) will be recorded on the subject’s case report 
form.  
3.5 SURGICAL GUIDELINES:   
If patients wish to seek whole gland therapy, subjects may undergo standard of care surgical 
treatment if clinic ally indicated.   
3.6 RADIATION THERAPY GU IDELINES:  
If patients wish to seek whole gland therapy, subjects may undergo standard of care radiation 
therapy if clinically indicated.  
3.7 CRITERIA FOR REMOVAL  FROM PROTOCOL INTERVENTIONS  AND OFF 
STUDY CRITERIA  
3.7.1 Criteria  for Stopping Laser Procedure  
During the laser procedure, outcome measures of importance that may interrupt or stop the 
procedure include the following:  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
26 
 3.7.1.1  Refusal to continue the treatment due to pain in spite of the opportunity to receive pain 
medication.  
3.7.1.2  Observing thermal damage on post contrast MRI which extends beyond the estimated 
damage maps from the Visualase software or which extends into areas of the Rectum or 
Urethra will be considered side effects for stopping purposes.  
3.7.1.3  Grade 3 or 4 toxicity attrib utable to the treatment.  
3.7.1.4  Patient choice for reasons other than those given above.  
3.7.1.5  The investigator feels it is in the best interest of the patient.  
3.7.2 Off-Study Criteria  
Once the laser focal ablation has been performed, the patient will continue participation  in this 
study until one of the following:  
3.7.2.1  Patients decides to withdraw from the study  
3.7.2.2  Death  
3.7.2.3  Protocol specified follow up (3 years) is completed  
3.7.2.4  The investigator determines it is in the patient’s best interest, due to an increase in 
Gleason score on follow -up biopsy or evidence of disease beyond the prostate  
The reason for withdrawal must be recorded on the appropriate part of the case report form.  
Authorized staff must notify Central Registration Office (CRO) when a subject is taken off  
protocol ther apy and when a subject is taken off study. A  Participant Status Updates F orm from 
the web site ( http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed an d sent via encrypted email to:  NCI Central Registration Office  
ncicentralregistration -l@mail.nih.gov . 
4 CONCOMITANT MEDICATI ONS/MEASURES:  
All immediate issues and complications relating to laser ablation procedure will be dealt with at 
the time of surgery.  Supportive care will be provided in accordance with the Standard Clinical 
practice core of good medical practice.  
  
5 BIOSPECIMEN COLLECTI ON 
5.1 TISSUE COLLECTION, S AMPLE STORAGE, TRACK ING AND DISPO SITION  
All specimens collected during this trial will be analyzed according to the specifications 
described in this protocol.  Excess samples obtained during participation in this trial may be used 
for research purposes if the subject has consented and enr olled on NIH NCI protocol 97 -C-0147.  
No research tissue analysis is specified in this protocol.  
Samples will be destroyed at the completion of this study unless subjects have consented to 
participate in protocol 97 -C-0147, in which case, specimens will be  handled according to the 
specifications of that protocol.  
The IRB will be notified in the event samples are inadvertently lost or destroyed.   At the 
completion of this study samples will either be destroyed or IRB approval will be sought if an 
alternate  disposition is determined.   
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
27 
 6 DATA COLLECTION AND EVALUATION  
6.1 DATA COLLECTION  
All patients must have signed an informed consent; and, an on study confirmation of eligibility 
form must be filled out before enrollment.  
Complete records must be maintained o n each patient.  These will consist of the hospital chart 
with any supplementary information obtained from outside laboratories, radiology reports, or 
physician's records.  These records will serve as the primary source material that forms the basis 
for th e research record.  All relevant data will also be entered on a computer data base from 
which formal analyses are done.  
The PI will be responsible for overseeing entry of data into an in -house password protected 
electronic system (Labmatrix) and ensuring data accuracy, consistency and timeliness. The 
principal investigator, associate investigators/research nurses and/or a contracted data manager 
will assist with the data management efforts.  All data obtained during the conduct of the 
protocol will be kept  in secure network drives or in approved alternative sites that comply with 
NIH security standards. Primary and final analyzed data will have identifiers so that research 
data can be attributed to an individual human subject participant.  
End of study proce dures: Data will be stored according to HHS, FDA regulations, and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or destruction of data: Should we become aware that a major breach in our plan to protect 
subject confidentiality and trial dat a has occurred, the IRB will be notified.  
The investigator, however, must maintain a list of subject names and identifying information. 
Subjects will be evaluated in their initial visit to the Clinical Center of the National Cancer 
Institute.  At this tim e the subject will meet with the principal investigator or his designee as well 
as a protocol research nurse to answer any questions that they may have.  During this evaluation 
the subject will also undergo a physical exam which includes a digital rectal e xam as well as 
basic blood work (PSA, CBC, CMP, and PT/PTT) and evaluation scans as listed in section 2.2.  
The subject’s records will be screened to determine if he is a candidate for the study. If the 
subject does not meet all of the inclusion or exclusi on criteria, he will be excluded from the 
study. Any biopsies, blood work, scans, or other clinical information obtained prior to presenting 
to the Clinical Center will also be requested at this time.   At this initial meeting the subject will 
also be aske d to fill out the IPSS, and SHIM evaluations. If any other tests have been performed 
in the evaluation of the subject’s prostate cancer, the results will be placed in the subject’s study 
file. These may include CXRs, CT scans, other imaging modalities, and /or biopsies. If any of 
these tests show there is metastatic disease, the subject will be excluded from the study.  
6.2 RESPONSE CRITERIA  
Follow up MRI of the pelvis at day 0, 1 and at 0.5, 1, 2, and 3 years.  The targeted lesions on 
MRI should demonstrate chan ges consistent with successful treatment (a decrease of 
enhancement on MP MRI ). (Scans can be obtained within +/ - 1 month of the target time table)  
Follow up systematic core biopsy of the prostate at 1, 2, and 3 (optional) years showing no 
evidence of invasive prostate cancer in the region of laser ablation.  (Biopsies can be obtained 
within +/ - 1 month of the target time table)  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
28 
 Standard and MR image guided biopsy of previous laser ablation sites should show no evidence 
of cancer.  
Follow up DRE and phys ical exam at 3, 6, 12, 18, 24 months and 3 years.  This should show no 
palpable disease, if disease is detected then further workup with one of the above mentioned tests 
will be preformed.  
6.3 TOXICITY CRITERIA  
The following adverse event management guidelines  are intended to ensure the safety of each 
patient while on the study.  The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE 
reporting.   A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ).  All appropriate 
treatment areas s hould have access to a copy of the CTEP Active Version of CTCAE.  
There currently is no large series of data regarding laser ablation of the prostate.  Large series of 
focal laser ablation of solid tumors reports an overall complication rate of 1.5% and a 3 0 day 
mortality rate of 0.1%.19  Trachtenberg et al20 reported a series of 12 patients.  There were no 
mortalities and the complication rates reported were as follows:  Postoperative morbidity was 
minimal, self -limited and required no intervention. Perineal discomfort was the most common 
side effect (25% of patients). Two patients had mild hematuria that did not require any 
intervention and cleared spontaneously, 2 patients had hematospermia and 1 had fatigue. Due to 
the limited paucity of information we will  also in cooperate and follow data points from the focal 
cryoablation data (table below).21 
 
 
7 SAFETY REPORTING REQ UIREMENTS/DATA AND S AFETY MONITORING 
PLAN   
7.1 DEFINITIONS  
7.1.1 Unanticipated Adverse Device Effect  
Unanticipated adverse device effect is any serious adverse effect on health or safety, any life -
threatening problem or death caused by, or associated with a device, if that effect, problem, or 
death was not previously identified in nature, severity, or deg ree of incidence in the application; 
or any other unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of subjects.  
 

Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
29 
 All adverse device effects  will be followed until return to baseline or stabilization of e vent.  
Unanticipated  adverse device effects  that occur more than 30 days after the last administration of 
investigational agent/intervention should be recorded and reported as per section 7.2. 
7.1.2 Serious  
An Unanticipated Problem or Protocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety, welfare or rights of subjects or others.  
7.1.3 Protocol Deviat ion (NIH Definition)  
Any change, divergence, or departure from the IRB -approved research protocol . 
7.1.4 Non-compliance (NIH Definition)  
The failure to comply with applicable NIH Human Research Protections Program (HRPP) 
policies, IRB requirements, or regulatory  requirements for the protection of human research 
subjects.  
7.1.5 Unanticipated Problem  
Any incident, experience, or outcome that:  
• Is unexpected in terms of nature, severity, or frequency in relation to  
(a) the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigator’s Brochure or other study documents, and  
(b) the characteristics of the subject population being studied; AND  
• Is related or possibly related to participation in the research; AND  
• Suggests that the research places subjects or others at a g reater risk of harm  (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
7.2 NCI-IRB AND CLINICAL DIRECT OR REPORTING  
7.2.1 NCI-IRB and NCI CD Expedited Reporti ng of Unanticipated Problems and Deaths  
The Protocol PI will report  in the NIH Problem Form  to the NCI -IRB and NCI Clinical Director : 
• All deaths, except deaths due to progressive disease  
• All Protocol Deviations  
• All Unanticipated Problems  
• All non-compliance  
Reports must be received within 7 days of PI awareness via iRIS.  
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
30 
 7.2.2 NCI-IRB Requirements for PI Reporting at Continuing Review  
The protocol PI will report to the NCI -IRB:  
1. A summary of all protocol deviations in a tabular format to include the  date the deviation 
occurred, a brief description of the deviation and any corrective action.  
2. A summary of any instances of non -compliance  
3. A tabular summary of the following adverse events:  
• All Grade 2 unexpected events that are possibly, probably or definitely related to the 
research;  
• All Grade 3 and 4 events that are possibly, probably or definitely related to the 
research;  
• All Grade 5 events regardless of attribution;  
• All Serious Events regardless of attribut ion.  
NOTE : Grade 1 events are not required to be reported.  
7.2.3 Non Reportable Occurrences secondary to the MRI or prostate biopsy.  
Patients may have events which we would not consider to be secondary to the laser treatment and 
therefore not reportable to the  IRB.  First, the MRI with gadolinium, there is a very low 
possibility they may develop an acute allergic reaction to the gadolinium, because the patients 
underwent the MR for the entry process to be screened for the study.  
Second, the prostate biopsies p erformed on the NIH protocol 05-CC-0091 with tissue and 
specimens acquired on the 97 -C-0147 protocol.  The patients may develop symptoms post 
biopsy: Urinary Frequency, Urinary Retention, Dysuria, Hematuria, Erectile Dysfunction, 
Urinary Tract Infection or  Urosepsis post biopsy, which we believe would not be reportable or 
included in the stopping criteria for the study since these symptoms are not attributed to the laser 
ablation, especially at the one year and two year biopsy timepoints.  
 
7.2.4 NCI-IRB Reporting  of Safety Reports  
Only Safety Reports that meet the definition of an unanticipated problem will need to be reported 
to the NCI IRB.  
 
7.3 EXPEDITED ADVERSE EV ENT REPORTING TO THE  MANUFACTURER  
If an unanticipated adverse device effect occurs, the investigator w ill immediately contact the 
manufacturer to report the event.  The manufacture r contact for reporting unanticipated adverse 
device effects will be:  
Ashok Gowda, Ph.D  
Chief Operating Officer  
Visualase, Inc.  
8058 El Rio St.  
Houston, TX 77054  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
31 
 Phone: (713) 741-0111  
FAX: (713) 741 -0122  
Co 
7.4 DATA AND SAFETY MONI TORING PLAN  
7.4.1 Principal Investigator/Research Team  
The clinical research team will meet on a regular basis when patients are being actively treated 
on the trial to discuss each patient in detail.    
All da ta will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator in a timely manner.  Adverse events will be reported as required above.  
Any safety concerns, new information that might affect either the e thical and or scientific 
conduct of the trial, or protocol deviations will be immediately reported to the IRB using iRIS ) 
and to the manufacturer.  
In addition, the PI and associate investigators will monitor adverse events on an ongoing basis 
and modify t he protocol and/or consent accordingly.  After the first 5 patients are treated, and 
again after the first 10 are treated, interim assessments will be performed by the PI and associate 
investigators.  This study will be stopped, and the IRB will be notifie d if adverse events develop 
which endanger patient safety, although the likelihood of this is so low that it is hard to create or 
imagine possible examples of such events.  
The principal investigator will review adverse event and response data on each patient to ensure 
safety and data accuracy.  The principal investigator will personally conduct or supervise the 
investigation and provide appropriate delegation of responsibili ties to other members of the 
research staff.  If there is mortality the study will be paused and a determination of cause will be 
pursued.  If the cause was due to the laser therapy the pilot study will be concluded.  Also, 
regarding other complications ra tes if the 30-day complication rate of serious events exceeds 2 
patients a further analysis of the technique will be performed, as well as pausing and possible 
concluding the study if changes cannot be made for improvement.   
 
8 STATISTICAL SECTION   
The pri mary goal of this study is to assess the toxicity, performance and feasibility of the 
Visualase thermal therapy procedure for focal prostate cancer treatment and then to monitor any 
complications for the 3 years following treatment.  The outcome measures o f importance during 
the thermal treatment are pain, frequency of thermal damage outside of intended treatment areas 
as measured by post contrast MRI, frequency of not completing the entire procedure, or the 
frequency of other adverse events and complicatio ns.  These outcome measures are further 
defined as follows:  
* Observing thermal damage on post contrast MRI which extends into areas of the 
Rectum or Urethra will be considered side effects for stopping purposes.  
* Frequency of not completing the procedure. No t completing the procedure for reasons 
other than those given above will be considered a side effect for stopping purposes.  
* Other adverse events or complications that occur that are classified as Grade 3 or 4 by 
the National Cancer Institute's Common Toxicity Criteria 4, will be considered a side 
effect for stopping purposes.  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
32 
 Sample size  
The purpose of the study is to assess the safety, performance and feasibility of the Visualase 
thermal therapy procedure for focal prostate cancer treatment.  The samp le size is targeted at 15 
evaluable patients which is adequate to assess the toxicity rate and can be reasonably recruited in 
a 6-month period of time. With the accrual of 15 patients, the width of the 80% expected 
confidence interval of 0.1 and 0.2  toxic ity rate is 0.19 and 0.26, respectively.  
Stopping rule  
For the purpose of protecting patient safety, we implement the following stopping rule for safety 
monitoring. If one patient experiences a grade 5 event, thought to be possibly or probably due to 
the laser therapy, the study will be stopped. For grade 3 or 4 event, the  study will be stopped 
according to the following stopping rule.  
Number of patients  No. of grade 3 or 4 serious adverse events  
3-5 3 
6-10 4 
11-15 5 
The operating characteristic of the  stopping rule was assessed by simulations. Based on 10,000 
simulations, the probability of stopping early for an excess of serious adverse event over the 
course of trial is 0.023 when the serious adverse event rate is 0.1 and 0.81 when the serious 
adverse  event rate is 0.40. This is deemed reasonable for protecting patient safety.  
Frequency of the outcome measures, response and toxicity will be reported.  Paired Student t test 
will be used to compare the difference between continuous variables (PSA, MRI im aging 
parameters) measured at baseline and at each follow -up visit. Prior to performing the paired t -
test, the distribution of the underlying data will be assessed, and adequate transformation will be 
undertaken to ensure that the distribution of the trans formed data is approximately normal. 
Descriptive statistics such as frequencies and percentages of categorical variables will be 
reported. In addition, McNemar’s test, though may not have adequate power for this pilot study, 
will be explored  to evaluate t he difference in proportion between baseline and at each follow -up. 
Longitudinal profiles of parameters recorded in the questionnaires over the course of follow -up 
for each patient will be plotted and the associated summary statistics such as mean, standard 
deviation, and mean change between successive follow -up visits will be reported.  In addition, 
linear and non -linear mixed effects models will be explored to model the longitudinal profiles of 
the parameters of interest. In these models, random in tercept will be used to incorporate the 
within -patient correlation of the repeated observations. If deemed appropriate, random slope will 
be added to the model to allow for the slope of profile to vary between patients.  
 
9 HUMAN SUBJECTS PROTE CTIONS  
Confide ntiality, individual choice and volunteerism are standard values of the UOB staff relative 
to their studies and practice.  The earliest patient education and counseling begins at the initial 
contact with one of the protocol nurse coordinators or investigat ors.  After arriving at the clinic, 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
33 
 subjects will have a dialog about: the disorder in question and the protocol study; questions are 
answered; information material is provided.  
As information is gathered from this trial, clinical results will be shared wi th patients while 
insuring total patient confidentiality.  Clinical data will be frequently gathered and any new 
significant findings(s) found during the course of the research, which may affect a patient’s 
willingness to participate further will be explai ned.  Moreover, in all publications and 
presentations resulting from this trial, patients' anonymity will be protected to the maximum 
extent possible; although, authorized personnel from the National Cancer Institute (NCI) and 
Food and Drug Administration (FDA) may have access to research files in order to verify that 
patient rights have been safeguarded.  
9.1 RATIONALE FOR SUBJEC T SELECTION  
Males of all racial/ethnic groups are eligible for this study if they meet the eligibility criteria.  
Efforts will be made  to extend accrual to a representative population.  
 
9.2 STRATEGIES/PROCEDURE S FOR RECRUITMENT  
Referrals from within the NIH will be welcomed.  This protocol also will be available through 
the NIH clinical trials data base at website address: http://clinicaltrials.gov/  
 
9.3 JUSTIFICATION FOR EX CLUSIONS  
Patients with altered mental status that prevents consent or answering questions will be excluded. 
Patients with uncorrectable coagulopathies may be at increased risk for bleeding, and will be 
excluded.  Patients with multiple co morbid illnesses, sepsis, or multiple high -risk medical 
problems may be at increased risk for morbidities or mortalities, and will be excluded at the 
judgment of the PI (Dr. Peter Pinto or his designee).  This does not change standard biopsy 
exclusions.  If a patient is unable to h old his or her breath for more than 5 seconds, the study data 
acquired may be potentially confounding and inaccurate.  
 
9.4 PARTICIPATION OF CHI LDREN   
Only patients 18 years or older will be enrolled in this study.  Prostate cancer is extremely rare in 
childr en. 
 
9.5 PARTICIPATION OF SUB JECTS UNABLE TO GIVE  CONSENT  
Adults unable to give consent are excluded from enrolling in the protocol.  However re -consent 
may be necessary and there is a possibility, though unlikely, that subjects could become 
decisionally impai red. For this reason and because there is a prospect of direct benefit from 
research participati on (section 9.6), all subjects  will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the “NIH Advance 
Directive for Health Care and Medical Research Participation” form so that another person can 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
34 
 make decisions about their medical care in t he event that they become incapacitated or 
cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH 
Ability to Consent Assessment Team for evaluation.  For those subjects that become 
incapacitated and do not have pre -determined substitute decision maker, the procedures 
described in MEC Policy 87 -4 for appointing a surrogate decision maker for adult subjects who 
are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of 
attorney, will be fo llowed.  
9.6 EVALUATION OF BENEFI TS AND RISKS/DISCOMF ORTS  
This study may be of benefit to subjects by allowing for an early, minimally invasive treatment 
for low grade confined prostate cancer, as compared to the current treatment standard.  It also 
offers an a lternative to those patients who would qualify for watchful -waiting but are 
uncomfortable with this approach.  Those patients who are involved in active surveillance must 
undergo yearly prostate biopsies that themselves are painful and carry with them a ri sk of 
infection and prostatitis.  The risks of this study are no greater than those of taking a watchful -
waiting approach to treating minimally invasive prostate cancer.   
However, for those patients who opt for this protocol there is a risk that their can cer may 
progress, either through the multifocal nature of prostate cancer or through the inaccuracy of the 
focally directed process.  For these patients, this risk is minimized through thorough follow up 
with imaging, biopsy, and close monitoring of PSA.  Finally, the discomfort that subjects may 
experience will be minimized as much as possible, however, prostate biopsies and post ablation 
pain may exist and this will be treated in accordance to the standard of care.  
 
9.7 RISKS/BENEFITS ANALY SIS – MONITORING OF  TRIAL  
Thus, we believe that this trial may eventually lead to improvements in the safety and delivery of 
ablation procedures.  Although no guarantee of any benefit whatsoever will be made to the 
patient, experience from pre -clinical trials makes us confid ent that there is no increased risk to 
the patient from using the tracked devices that differ very little from conventional needles.  
Focal thermal therapy for prostate cancer offers a treatment option intermediate between active 
surveillance and radical therapy for small volume, low grade prostate cancer.  It prevents the side 
effects of radical therapy and may help decrease the chances  of disease progression in active 
surveillance.  
Potential risks associated with use of the Visualase laser thermal therapy system include 
bleeding, infection, pain, urinary tract symptoms, and damage to the rectal wall, bladder 
problems, and erectile dysf unction.  Visualase applicator placement will be performed under 
sterile conditions with appropriate anesthesia (local, spinal, or general).  If a course of 
prophylactic antibiotics or analgesics is administered according to standard clinical practice for 
this type of procedure, this information should be documented as a concomitant medication.  
Potential risks associated with the thermal ablation treatment include pain, thermal injury to the 
adjacent organs, erectile dysfunction, the inability to urinate, a nd blood in the urine.  MR -
thermometry and feedback control using the Visualase system minimize the risk of overheating 
critical structures or areas outside of the intended target tissue.  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
35 
 No serious side effects or complications have been observed in any p atients treated to -date with 
thermal ablation using Visualase.  
Minimal risks are inherent within this protocol and include the physical risks of phlebotomy, and 
imaging contrast.    
• Risk Level: Likely but not serious:     
o Risks from a skin puncture (perineum) include some discomfort associated 
with percutaneous analgesia and a risk of bruising, small scar formation, and a 
small chance of infection.   
o Voiding irritation frequency and urgency after the procedure secondary to 
urinary catheter which should be self resolving within a few days if removal.  
o Urinary retention after catheter removal.  
o The safety and efficacy of gadolinium contrast has been well documented and 
a reaction is less likely while on protocol, due to all pat ients required an MRI 
with gadolinium to be evaluated as a possible candidate  
o Minimal risks are associated with the medical procedure of obtaining blood 
and include some discomfort and bruising.   
• Risk Level: Unknown incidence but not serious  
o Erectile Dysf unction  
o Hematuria  
• Risk Level:  No known risk:   
o There are no known health hazards of ultrasound or MRI at power levels 
employed for diagnostic purposes  
• Risk Level:  Very unlikely, but serious:    
o Urinary fistula from ablation of the prostate with rectum.   
The PI will continue to monitor the study along with reporting adverse events to the IRB.  If 
there is mortality the study will be paused and a determination of cause will be pursued.  If the 
cause was due to the laser therapy the pilot study will be conc luded.  Also, regarding other 
complications rates if the 30 day complication rate of serious events exceeds 2 patients a further 
analysis of the technique will be performed as well as pausing and possible concluding the study 
if changes cannot be made for improvement.   
 
9.8 CONSENT PROCESS AND DOCUMENTATION  
The investigator will inform patients and their family members (if appropriate) of the purpose, 
alternatives, treatment plan, research objectives and follow -up of this trial.  The investigator will 
then pro vide a copy of the IRB -approved informed consent document for this study.  The patient 
will be allowed to take as much time as he/she wishes, in deciding whether or not to participate. 
The original signed consent goes to Medical Records; copy placed in res earch record.  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
36 
 All patients must have a signed informed consent form and an on -study (confirmation of 
eligibility) form filled out and signed by a participating investigator before entering on the study.  
For the optional research biopsy in the  in the protocol, the patient will consent at the time of the 
procedure.  If the patient refuses the optional biopsy at that time, the refusal will be documented 
in the medical record and in the research record.  
9.8.1 Telephone consent  
The informed consent docum ent will be sent to the subject.  An explanation of the study will be 
provided over the telephone after the subject has had the opportunity to read the consent form.  
The subject will sign and date the informed consent. A witness to the subject’s signature  will 
sign and date the consent.  
The original informed consent document will be sent back to the consenting investigator who 
will sign and date the consent form with the date the consent was obtained via telephone.   
A fully executed copy will be returned  via mail for the subject’s records.  
The informed consent process will be documented on a progress note by the consenting 
investigator and a copy of the informed consent document and note will be kept in the subject’s 
research record.  
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
37 
 10 APPENDICES  
10.1 APPENDIX  A - INTERNATIONAL P ROSTATE SYMPTOM SCOR E (IPSS)  
Name:        Date:  
 
Not at all  
Less than 1 
time in 5  
Less than half 
the time  
About half 
the time  
More than 
half the time  
Almost 
always  
Your score  
Incomplete emptying  
Over the past month, how often have you had a sensation of not emptying 
your bladder completely after you finish urinating?  0 1 2 3 4 5  
Frequency  
Over the past month, how often have you had to urinate again less than two 
hours after you finished urinating?  0 1 2 3 4 5  
Intermittency  
Over the past month, how often have you found you stopped and started 
again several times when you urinated?  0 1 2 3 4 5  
Urgency  
Over the last month, how difficult have you found it to postpone urination?  0 1 2 3 4 5  
Weak stream  
Over the past month, how often have you had a weak urinary stream?  0 1 2 3 4 5  
Straining  
Over the past month, how often have you had to push or strain to begin 
urination?  0 1 2 3 4 5  
 
 
None  
1 time  
2 times  
3 times  
4 times  
5 times or 
more  
Your score  
Nocturia  
Over the past month, many times did you most typically get up to urinate 
from the time you went to bed until the time you got up in the morning?  0 1 2 3 4 5  
 
Total IPSS score  
  
 
Quality of life due to urinary symptoms  
 
 
 
 
Delighted  
Pleased  
Mostly satisfied  
Mixed – about 
equally satisfied and 
dissatisfied  
Mostly dissatisfied  
Unhappy  
Terrible  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
38 
 If you were to spend the rest of your life with your urinary condition the 
way it is now, how would you feel about that?  0 1 2 3 4 5 6 
 
Total score: 0-7 Mildly symptomatic; 8 -19 moderately symptomatic; 20 -35 severely symptomatic.  
10.2 APPENDIX  B - SEXUAL HEALTH INVENTORY FOR MEN  
 
PATIENT INSTRUCTIONS  
 
Sexual health is an important part of an individual's overall physical and emotional well -being. Erectile dysfunction, also known as 
impotence, is one type of very common medical condition affecting sexual health. Fortunately, there are many different treatment  
options for erectile dysfunction. This questionnaire is designed to help you and your doctor identify if you may be experienc ing e rectile 
dysfunction. If you are, you may choose to discuss treatment options with your doctor.  
 
Each question has several possible responses. Circle the number of the response that best describes  your own situation. Please 
be sure that you select one and only one response for each question . 
 
OVER THE PAST 6 MONTHS : 
 
1. How do you rate your confidence that you could get and keep an erection?  
 
 
Very low  Low Moderate  High Very high  
1 2 3 4 5 
 
 
2. When you had erections with sexual stimulation, how often were your erections hard enough for penetration (entering your 
partner)?  
 
 
No sexual activity  Almost never or 
never  A few times (much 
less than half the 
time)  Sometimes (about 
half the time)  Most times (much 
more than, half 
the time)  Almost always or 
always  
0 1 2 3 4 5 
 
3. During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?  
 
 
Did not attempt 
intercourse  Almost never or 
never  A few times (much 
less than half the 
time)  Sometimes (about 
half the time)  Most times (much 
more than, half 
the time)  Almost always or 
always  
0 1 2 3 4 5 
 
4. During sexual intercourse, how difficult was it to maintain your erection to completion of  intercourse?  
 
Did not attempt 
intercourse  Extremely difficult  Very difficult  Difficult  Slightly difficult  Not difficult  
0 1 2 3 4 5 
 
5. When you attempted sexual intercourse, how often was it satisfactory for you?  
 
 
Did not attempt 
intercourse  Almost never or 
never  A few times (much 
less than half the 
time)  Sometimes (about 
half the time)  Most times (much 
more than, half 
the time)  Almost always or 
always  
0 1 2 3 4 5 
 
 
 
 
SCORE ________________  
 
Add the numbers corresponding to questions 1 -5. If your score is 21 or less, you may want to speak with your  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
39 
  
 
10.3 APPENDIX C – BIOPSY CRITERIA ILLUSTRATIO NS 
APEXMIDBASE
APEXMIDBASEMulti -parametric MR TargetsBiopsy Proven 
Cancer Targets
MR Targets
BIOPSY Positive 
TARGETS
BIOPSY Negative 
TARGETS The patient is a candidate:
If both targets are positive (MR Targeted Biopsy <4 cores) for two targets
and it overlaps with the standard biopsy
The standard 12 core 
biopsy will have <3 
core positive and 
overlap zones with 
locations of target 
biopsies.
Left           Right
++Positive Biopsy
 
APEXMIDBASE
APEXMIDBASEMulti -parametric MR TargetsBiopsy Proven 
Cancer Targets
MR Targets
BIOPSY positive 
TARGETS
BIOPSY NEGATIVE 
TARGETS The patient is a candidate:
If one of the two targets are positive (MR Targeted Biopsy <4 cores) for one of 
the two targets and it overlaps with the standard biopsy.
The standard 12 core 
biopsy will have <3 
core positive and 
overlap zones with 
locations of target 
biopsies.
Left           Right
Positive Biopsy
+
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
40 
 
APEXMIDBASE
APEXMIDBASEMulti -parametric MR TargetsBiopsy Proven 
Cancer Targets
MR Targets
BIOPSY positive 
TARGETS
BIOPSY NEGATIVE 
TARGETS The patient is NOT a candidate:
If all Three targets are positive (MR Targeted Biopsy >4 cores) for three 
targets
The standard 12 core 
biopsy will have <3 
core positive and 
overlap zones with 
locations of target 
biopsies.
Left           Right
+
+Positive Biopsy 
APEXMIDBASE
APEXMIDBASEMulti -parametric MR TargetsBiopsy Proven 
Cancer Targets
MR Targets
BIOPSY positive 
TARGETS
BIOPSY NEGATIVE 
TARGETS The patient is NOT a candidate:
If all targets are negative (MR Targeted Biopsy >4 cores) for two targets
The standard 12 core 
biopsy will have <3 
core positive and 
overlap zones with 
locations of target 
biopsies.Left           Right
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
41 
 
APEXMIDBASE
APEXMIDBASEMulti -parametric MR TargetsBiopsy Proven 
Cancer Targets
MR Targets
BIOPSY positive 
TARGETS
BIOPSY NEGATIVE 
TARGETS The patient is NOT a candidate:
If both targets are positive (MR Targeted Biopsy <4 cores) for two targets
however there is no overlap with standard biopsy. Cancer was found in 
another location
The standard 12 core 
biopsy will have <3 
core positive and 
overlap zones with 
locations of target 
biopsies.
Left           Right
+
+Positive Biopsy 
 
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
42 
 10.4 APPENDIX D: STUDY CA LENDAR  
Procedure  Screenin
g/ 
Baseline  Treatment  
Day 
0 Day 
1 3 
Mos 6 
Mos 12 
Mos 18 
Mos 24 
Mos 36 
Mos 
History and PE  X X X X X X X X X 
Digital rectal exam  X  X X X X X X X 
Vital signs  X X  X X X X X X 
NIH Advanced 
Directives Form1  
X         
Labs           
CBC  X   X X X X X X 
PT/PTT/INR  X   X X X X X X 
Chem 7  X   X X X X X X 
PSA blood level  X   X X X X X X 
CMP  X         
Urinalysis and 
culture  X   X X X X X X 
Prostate Biopsies  
(10-12 cores)  X         
Prostate biopsy 
F/U      X  X Xb 
Thermal Therapy   X        
Metastatic disease 
work up: may 
include CT or MRI 
or Bone scanc X         
MR Imaging  X X X  X X  X X 
Trans rectal 
ultrasound  X         
Questionnaires 
(IPSS, SHIM)  X   X X X X X X 
Response 
Evaluation  X X X  X X  X X 
Adverse Events   X      X X 
Concomitant 
Medications   X      X X 
1 As indicated in section 9.5 all subjects  will be offered the opportunity to complete an NIH advanced directives 
form.  This should be done preferably at baseline but can be done at any time during the study as long as t he 
capacity to do so is retained.  The completion of the form is strongly recommended, but is not required.  
 
  
Version Date: 07/13/2017  
CC Protocol # : 11-C-0158  
Amendment G 
Image Guided Focal Prostate   
43 
 11 REFERENCES  
1  American Cancer Society: Cancer Facts and Figures 2007. American Cancer Society, 2007.  
2  Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, 
Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell  JM, Riley TL, Hayes RB, Kramer BS, 
Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Mortality results 
from a randomized prostate -cancer screening trial. N Engl J Med. 2009 Mar 26;360(13):1310 -9. 
3  Schröder FH, Hugosso n J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, 
Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der 
Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investi gators. Screening and prostate -
cancer mortality in a randomized European study . N Engl J Med. 2009 Mar 26;360(13):1320 -8. 
4  Adolfsson, J. (2008). Watchful waiting and active surveillance: The current position. BJU International, 2008: 
102(1), 10 -14. 
5   Epstein JI, Walsh PC, Carmichael M et al: Pathologic and clinical findings to predict tumor extent of 
nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368. 
6  Krakowsky Y, Loblaw A, Klot z L. Prostate cancer death of men treated with initial active surveillance: clinical 
and biochemical characteristics. J Urol. 2010 Jul;184(1):131 -5 
7  Singh, A. K., Kruecker, J., Xu, S., Glossop, N., Guion, P., Ullman, K. et al.: Initial clinical experienc e with real -
time transrectal ultrasonography -magnetic resonance imaging fusion -guided prostate biopsy. BJU Int, 101 : 841, 
2008.  
8  Ritch, C. R., Katz, A. E.: Prostate cryotherapy: current status. Curr Opin Urol, 19: 177, 2009  
9  Jemal, A., Murray, T., Ward , E. et al.: Cancer Statistics, 2005. CA Cancer J Clin, 55: 10, 2005  
10  Blana, A., Rogenhofer, S., Ganzer, R. et al.: Eight years' experience with high -intensity focused 
ultrasonography for treatment of localized prostate cancer. Urology, 72: 1329, 2008  
11  Jolesz, F. A., Hynynen, K., McDannold, N. et al.: MR imaging -controlled focused ultrasound ablation: a 
noninvasive image -guided surgery. Magn Reson Imaging Clin N Am, 13: 545, 2005  
12  Puech, P., Huglo, D., Petyt, G. et al.: Imaging of organ -confined prost ate cancer: functional ultrasound, MRI 
and PET/computed tomography. Curr Opin Urol, 19: 168, 2009  
13  Kurhanewicz, J., Vigneron, D., Carroll, P. et al.: Multiparametric magnetic resonance imaging in prostate 
cancer: present and future. Curr Opin Urol, 18: 7 1, 2008  
14  Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound 
therapy and active MR temperature feedback. Chopra R, Tang K, Burtnyk M, Boyes A, Sugar L, Appu S, Klotz 
L, Bronskill M. Phys Med Biol.  2009 May 7;54(9):2615 -33. Epub 2009 Apr 8.  
15  Computational modeling and real -time control of patient -specific laser treatment of cancer.   Fuentes D, Oden 
JT, Diller KR, Hazle JD, Elliott A, Shetty A, Stafford RJ.  Ann Biomed Eng. 2009 Apr;37(4):763 -82. Epub 
2009 Jan 16.  
16  Lindner U, Lawrentschuk N, Weersink RA, Davidson SR, Raz O, Hlasny E, Langer DL, Gertner MR, Van der 
Kwast T, Masoom HA, Trachtenberg J.: Focal Laser Ablation for Prostate Cancer Followed by Radical 
Prostatectomy: Validation of Focal T herapy and Imaging Accuracy. Eur Urol. 2010 Mar 12  
17  Best practice policy statement on urologic surgery antimicrobial prophylaxis. Wolf JS Jr, Bennett CJ, 
Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ; Urologic Surgery Antimicrobial Prophylaxis Be st 
Practice Policy Panel. J Urol. 2008 Apr;179(4):1379 -90. Epub 2008 Feb 20.  
18  Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick 
AC. Renal cryoablation: outcome at 3 years. J Urol. 2005 Jun;173(6):1903 -7.  
19  Vogl TJ, Straub R, Eichler K, Söllner O, Mack MG. Colorectal carcinoma metastases in liver: laser -induced 
interstitial thermotherapy --local tumor control rate and survival data.  Radiology. 2004 Feb;230(2):450 -8. Epub 
2003 Dec 19.  
20  Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, Wilson BC, Fenster A, Trachtenberg 
J. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009 
Oct;182(4):1371 -7. Epub 2009 Aug 14.  
21  Langenhuij sen JF, Broers EM, Vergunst H. Cryosurgery for prostate cancer: an update on clinical results of 
modern cryotechnology. Eur Urol. 2009 Jan;55(1):76 -86. Epub 2008 Sep 2.  
                                                  